Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder

V. Leclerc, M. Molimard, S. Rouanet, E. Vicaut, G. Lefrancois, P. A. Monici Preti (Courbevoie, Parma, France)

Source: Annual Congress 2003 - Issues surrounding drug delivery
Session: Issues surrounding drug delivery
Session type: Thematic Poster Session
Number: 2986
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Leclerc, M. Molimard, S. Rouanet, E. Vicaut, G. Lefrancois, P. A. Monici Preti (Courbevoie, Parma, France). Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder. Eur Respir J 2003; 22: Suppl. 45, 2986

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients
Source: Eur Respir J 2003; 22: Suppl. 45, 284s
Year: 2003

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 156s
Year: 2001

Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects
Source: Eur Respir J 2001; 18: Suppl. 33, 50s
Year: 2001

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001

Patients’ ability to use a novel fluticasone propionate/formoterol breath-triggered inhaler (BTI) vs. budesonide/formoterol dry powder inhaler (DPI)
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



A new nonultra fine BDP HFA 134a formulation: clinical equivalence of efficacy and safety versus CFC formulation
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

A comparison of once daily (evening) versus twice daily budesonide therapy from a new multi-dose dry powder inhaler versus twice daily therapy from a conventional dry powder inhaler in children
Source: Eur Respir J 2001; 18: Suppl. 33, 121s
Year: 2001

Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012


Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001

Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children
Source: Eur Respir J 2001; 18: Suppl. 33, 289s
Year: 2001

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004